



Cor/log® Probe 1P by emka MEDICAL
an opportunity for investment

Providing continuous monitoring of pulmonary arterial pressure for heart failure patients

Due to its strong positive medical impact and its high economic potential, Cor/log Probe 1P was awarded the Seal of Excellence by the EU-Horizon-2020 program and receives funding from the Bavarian Ministry of Economy.

A weak heart is the most common cause of hospital admission (400,000 cases per year in Germany alone). In hospitals, 39% of deaths are caused by heart failure.

In Germany, the Federal Joint Committee (G-BA), the highest decision-making body for health insurance funding, has approved reimbursement of up to 10k€ for systems able to continuously monitor pulmonary artery pressure.

This decision is based on recognizing that better management of heart failure patients, made possible by devices such as Cor/log Probe 1P, will provide better medication management and faster mobilization of patients, both factors leading to better quality of life for the patients, faster recovery and lower cost to the health system.

Field proven technology

Cor/log Probe 1P is already used for preclinical applications in pharma industry laboratories worldwide by our partner emka TECHNOLOGIES in Paris. In such pharma labs, the technology runs under the brand name easyTEL+. easyTEL+ implants have been running in laboratory animals for more than one year.




Electrocardiogram and blood pressure recorded from implanted dogs using emka TECHNOLOGIES easyTEL+ implants.

The final goal

Patient carries Cor/log Connect.


Data is logged for later inspection by physicians.



Fully mobile patient in and outside the hospital.

Medical certification

Cor/log Probe 1P being a medical device requires approved certification before it can be used and sold. Medical product certification is one of the speciality and strong expertise of the emka MEDICAL team. The certification process is well under way and we expect final approval by the regulatory EU rules around October 2018, in this configuration:



Team, premises, equipment

Our emka MEDICAL team in Aschaffenburg consists of 6 scientists, engineers and technicians with high expertise in medical device development and certification. When necessary they can draw support from the 25 people team of emka TECHNOLOGIES in Paris.

Equipment and systems in place in the Aschaffenburg premises allow for:

- certified design, production and quality management,
- production machinery and clean room of 60 sqm, (out of 1,500 sqm facility),
- proven annual production volume of 6.000 pcs in one shift easy to ramp up to 12,000 pcs annually

Business plan

Our business plan evaluation is supported by numerous discussions and contacts with key opinion leaders in Germany. Our sales efforts will be augmented by a partnership with a team already specializing in sales to German hospitals in the cardio vascular field.

The fact that Cor/log Probe 1P fits as a product eligible for reimbursement by the German health insurance is also a very positive factor. Based on these elements and on a cautious marketing assessment we plan to achieve the following numbers:

	2019	2020	2021	2022
Pcs.	300	1.500	3.700	9.000
Turnover (k€)	900	5.000	13.000	30.000
Profit (k€)	-190	400	3.500	7.800

Opportunity for investment

emka MEDICAL wishes to raise up to 500k€ in capital in order to fund the final stages of Cor/log Probe 1P certification and initiate the first sales in the coming 9 months. Current value of the company is estimated at 2.2M€. Assuming there is 500k€ of new capital, an investor bringing 30k€ will own around 1% of emka MEDICAL, after execution of the cash infusion, partial amounts also accepted.

Exit strategy

Our strategy is to bring emka MEDICAL to a point where it is of interest to an investment fund or a large biomedical company wishing to acquire it and bring it further, possibly, onto the US market. A reasonable target is to resell in 3 to 5 years for a value of 20 to 50M€.

As an example: CardioMEMS, an implanted device monitoring pressure, once it obtained FDA approval, was purchased 2 years ago by St. Jude for 400MUS\$.

Investor protection

Our implicit shareholder agreement is that, should we find an opportunity to sell the company, the majority shareholders commit not to sell their shares unless they guaranty the possibility for any other minority shareholder to also exit under the same conditions if they wish.

Aschaffenburg, July 2018



Please contact

Raymond Glocker, PhD
managing director of emka MEDICAL
mobile phone +49-162-2567405
r.glocker@emka-medical.de

emka MEDICAL GmbH

Erthalstraße 12
D-63739 Aschaffenburg
T: +49 (0)6021 / 4434522
F: +49 (0)6021 / 4434523
Website: www.emka-medical.de



Gefördert durch



Bayerisches Staatsministerium für
Wirtschaft und Medien, Energie
und Technologie